Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?

JAMA. 2020 Feb 25;323(8):713-715. doi: 10.1001/jama.2019.22524.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Administration, Intravenous
  • Humans
  • Interferon beta-1a
  • Pharmaceutical Preparations*
  • Respiration, Artificial
  • Respiratory Distress Syndrome* / drug therapy

Substances

  • Pharmaceutical Preparations
  • Interferon beta-1a